Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease

Table 3 Interaction of individual CSF biomarkers on evolution of MMSE using linear mixed-effects model

CSF biomarker	Time point	Interaction	95% CI	t	P
Aβ₄₂/t-tau	Time 6	0.1995	− 0.1375, 0.5365	1.1532	0.2492
	Time 12	0.3142	0.0002, 0.6282	1.9489	0.0517
	Time 18	0.7158	0.4114, 1.0201	4.5804	0.0000
	Time 24	0.7278	0.3980, 1.0576	4.2976	0.0000
	Time 30	0.6932	0.3525, 1.0339	3.9628	0.0001
	Time 36	0.8985	0.5423, 1.2548	4.9123	0.0000
Aβ₄₂	Time 6	0.0011	−0.0006, 0.0028	1.2622	0.2073
	Time 12	0.0013	− 0.0004, 0.0030	1.5417	0.1236
	Time 18	0.0028	0.0011, 0.0046	3.2476	0.0012
	Time 24	0.0030	0.0012, 0.0049	3.1770	0.0015
	Time 30	0.0030	0.0009, 0.0052	2.7235	0.0066
	Time 36	0.0035	0.0014, 0.0056	3.2335	0.0013
p₁₈₁-tau	Time 6	−0.0084	−0.0252, 0.0085	−0.9701	0.3323
	Time 12	−0.0133	−0.0294, 0.0029	−1.5972	0.1106
	Time 18	−0.0267	−0.0438, − 0.0096	−3.0428	0.0024
	Time 24	−0.0225	−0.0398, − 0.0052	−2.5298	0.0116
	Time 30	−0.0220	−0.0405, − 0.0036	−2.3239	0.0204
	Time 36	−0.0376	−0.0585, − 0.0168	− 3.5146	0.0005
t-tau	Time 6	−0.0009	− 0.0030, 0.0011	− 0.8744	0.3821
	Time 12	−0.0018	−0.0037, 0.0002	−1.7530	0.0800
	Time 18	−0.0042	−0.0062, − 0.0022	−4.1350	0.0000
	Time 24	−0.0035	−0.0056, − 0.0014	−3.2733	0.0011
	Time 30	−0.0036	−0.0058, − 0.0014	−3.1591	0.0016
	Time 36	−0.0050	−0.0075, − 0.0026	−4.0395	0.0001

CSF cerebrospinal fluid, CI confidence interval. Model is corrected for age and sex. Time 6 corresponds to the period 0–0.5 year; time 12 corresponds to the period 0.5–1 year; time 18 corresponds to the period 1–1.5 year; time 24 corresponds to the period 1.5-2 year; time 30 corresponds to the period 2–2.5 year; time 36 corresponds to the period 2.5–3 year. Significant p-values are represented in bold

ISSN: 1758-9193